Get 40% Off
🤯 This Tech Portfolio is up 29% YTD! Join Now to Get April’s Top PicksGet The Picks – Just 99 USD

SVB Sees De-Risked Opportunity For This This Newly Listed Norovirus Vaccine

Published 24/05/2022, 20:40
Updated 24/05/2022, 21:42
© Reuters.  SVB Sees De-Risked Opportunity For This This Newly Listed Norovirus Vaccine

© Reuters. SVB Sees De-Risked Opportunity For This This Newly Listed Norovirus Vaccine

  • SVB Leerink is initiating coverage of HilleVax Inc (NASDAQ: HLVX) shares with an Outperform rating and a $30 price target.
  • The analyst believes the company’s potentially first-in-class infant norovirus vaccine HIL214 represents a uniquely de-risked opportunity.
  • It estimates $625 million in risk-adjusted infant HIL214 sales in 2030E ($1 billion unadjusted).
  • The outlook is supported by the pediatric rotavirus vaccine analog (2021 global sales of Rotateq and Rotarix combined were $1.6 billion).
  • The company also plans to study HIL214 in older adults, which could represent a second blockbuster indication.
  • SVB also noted that HLVX shares had traded down -41% post IPO vs. -5% for the XBI, likely due to market dislocation.
  • It believes this provides an attractive entry point for investors as HLVX’s $380 million market cap appears heavily discounted vs. its $1.2 billion discounted cash flow-based valuation.
  • SVB expects infant Phase 2b safety data in 2H22, immunogenicity data in 1H23, and top-line efficacy data in 2H23.
  • Concurrently, Guggenheim initiated coverage on HilleVax with a Buy rating and a price target of $40. JP Morgan initiated coverage on HilleVax with an Overweight rating and a price target of $24.
  • Price Action: HLVX shares are up 8.68% at $10.33 during the market session on the last check Tuesday.
© 2022 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.

Read at Benzinga

Read the original article on Benzinga

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.